🔇 Silence detected
Q4 FY26
Aarti Drugs Limited
Management stopped discussing '15-20% revenue growth aspiration for FY27' — last mentioned in Q3 FY26.
Track what management promises — and whether they deliver.
The only platform that scores Indian management teams on accountability across quarters.
0 companies tracked
0 quarters processed
0 filing-verified pages
Q4 FY26 sentiment
464 bullish
152 neutral
26 bearish
ConCallIQ research desk
Latest call brief
Dr. Reddy's Laboratories · Q2 FY26
Dr.
₹8,828 CrRevenue
₹1,337 CrPAT
neutralSentiment
Risk watchlistDr. Reddy's Laboratories
Promise ledgerHistorical backfill in progress
Recent Alerts
Management behavior changes across the latest quarter.
Silence, guidance cuts, tone shifts, missed promises, and bear-case verdict changes surfaced from the latest published data.
🔇 Silence detected
Q4 FY26
Aarti Drugs Limited
Management stopped discussing 'Capex of ₹150-200 crore per year for next two years' — last mentioned in Q3 FY26.
🔇 Silence detected
Q4 FY26
Aarti Drugs Limited
Management stopped discussing 'Domestic antibiotic demand weakness' — last mentioned in Q3 FY26.
🔇 Silence detected
Q4 FY26
Aarti Pharmalabs Limited
Management stopped discussing 'Atali greenfield plant commercial production by end of Q2 FY26' — last mentioned in Q3 FY26.
🔇 Silence detected
Q4 FY26
Aarti Pharmalabs Limited
Management stopped discussing 'CDMO revenue guidance for FY26 maintained' — last mentioned in Q3 FY26.
This Week's Wrap
ReliancePromise of the week
TCSAlive bear case
Varun Beverages6→8 confidence
Why ConCallIQ?
Not another loose AI summary. A structured earnings intelligence layer.
- 2-minute summariesRead the result, driver, guidance, risk, and quotes without opening a one-hour transcript.
- Management accountabilityTrack promises across quarters as historical data gets backfilled.
- Verified dataPublished financial fields are gated by filing or Screener-backed verification.
2-minute earnings brief
A crisp analyst-style readout covering what happened, why it happened, what management said next, and the clearest risk to monitor.
Management promise ledger
Quarter-by-quarter accountability for guidance, capex plans, launches, margin promises, and demand commentary as history gets backfilled.
Risk radar
Surfaces the specific operational, regulatory, margin, demand, and execution risks hidden inside long calls before they become consensus headlines.
Verified number spine
Revenue, EBITDA, PAT, margins, and key deltas carry an explicit filing-verification status so transcript-derived figures are not mistaken for checked numbers.
Key Risks Across Recent Calls
Risks highlighted by management across the latest earnings season.
Dr. Reddy's Laboratories · Q2 FY26 · high
Form 483s with 5 observations at Bachupalli Biologics, 7 at Mirfield API site and Srikakulam facility.
Anlon Technology Solutions · Q4 FY26 · highGrowth is tied to government infrastructure spending and Make in India policy; any policy shift could impact order flow.
Chembond Chemicals · Q4 FY26 · highKey inputs (zinc, molybdenum) have risen sharply, causing ~3% margin impact. Management expects 1-2 quarters to pass through costs, but prolonged inflation could compress margins.
Kfin Technologies · Q4 FY26 · highContinued mark-to-market erosion and retail investor exodus could further compress yields and delay revenue recovery in issuer solutions.
Coverage
908 Indian listed companies and growing
Coverage is generated from the local earnings dataset and expands as new transcripts, filings, and validated summaries enter the pipeline.
View all companies →
Diversified1388 pagesInformation Technology125 pagesFinancial Services104 pagesConsumer80 pagesHealthcare70 pagesEnergy64 pages
Latest Earnings
Dr. Reddy's Laboratories · Q2 FY26
neutral
medium
Dr.
Read analysis →
Blue Water Logistics · Q4 FY26
bullish
high
Blue Water Logistics delivered a stellar Q4 FY26 with revenue surging 97% YoY to ₹386 crore, driven by strong demand across logistics verticals, expansion of asset base, and new...
Read analysis →
Anlon Technology Solutions · Q4 FY26
bullish
high
Anlon Technology Solutions reported a stellar FY26 with revenue doubling to ₹105.92 Cr (+111% YoY) and PAT surging 114% to ₹13.88 Cr, driven by a strategic shift to indigenous m...
Read analysis →
Aegis Logistics · Q4 FY26
bullish
high
Aegis Logistics delivered a breakout FY26 with revenue of 8,333 crores (+23% YoY), normalized EBITDA of 1,599 crores (+36% YoY), and PAT of 1,117 crores (+41% YoY), crossing the...
Read analysis →
Chembond Chemicals · Q4 FY26
bullish
medium
Chembond Chemicals reported a strong Q4 FY26 with consolidated revenue of 101.4 crores, the highest in nine quarters, and full-year revenue of 326.15 crores (+12% YoY).
Read analysis →
Kfin Technologies · Q4 FY26
neutral
medium
KFin Tech reported Q4 FY26 consolidated revenue growth of 23% YoY, but EBITDA grew only 5% YoY and PAT was flat, impacted by mark-to-market erosion in equity markets, a shift to...
Read analysis →Pricing
Start free. Upgrade when you want the full picture.
All public pages stay open while Pro adds deeper scorecards, watchlist alerts, trend pages, annual summaries, and Hindi coverage.
Free
Start with the latest earnings-call intelligence for Indian equities.
₹0forever
- Latest quarter summaries
- Company pages
- Key numbers and guidance
- Risk highlights
- Company search
- Sector browsing
Pro
For investors who want the full management-accountability picture.
₹249per month · ₹2,499/year saves 17%
- Everything in Free
- Full management scorecard backfill across all quarters
- Watchlist with alerts
- Revenue, margin, and PAT trend pages
- Guidance tracker pages
- Annual summary pages
- Priority coverage requests
- Hindi summaries
Research Notes
5 min read
Management commentary is data. Most investors still treat it like theatre.
The earnings edge is not the headline PAT number. It is the trail of promises, hedges, guidance, and execution gaps that compounds over quarters.
4 min readWhy concall summaries are not enough
A summary gets you oriented. A promise ledger tells you whether management actually did what it said it would do.
6 min readHow ConCallIQ keeps generated earnings pages grounded
A short explanation of why generated pages must pass schema checks, filing-backed financial validation, and internal link validation before publishing.